Search research articles

Search research articles

Related Experiment Videos

Refractory Inflammatory Bowel Disease.

Karl H. Kim¹, Gary R. Lichtenstein

¹Division of Gastroenterology, Department of Medicine, University of Pennsylvania School of Medicine, 3400 Spruce Street, 3rd Floor Ravdin Building, Philadelphia, PA 19104-4283, USA. grl@uphs.upenn.edu

Current Treatment Options in Gastroenterology

|May 20, 2004

Summary

This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

The role of biological therapy in inflammatory bowel disease.

Drugs of today (Barcelona, Spain : 1998)·2003

Same author

Refractory Inflammatory Bowel Disease.

Current treatment options in gastroenterology·2001

Same journal

Esophageal Disorders in the Older Adult.

Current treatment options in gastroenterology·2025

Same journal

Endobariatrics: a Still Underutilized Weight Loss Tool.

Current treatment options in gastroenterology·2023

Same journal

Management of Post Ablative Barrett's Esophagus: a Review of Current Practices and Look at Emerging Technologies.

Current treatment options in gastroenterology·2023

Same journal

Inflammatory Bowel Disease Therapy and Venous Thromboembolism.

Current treatment options in gastroenterology·2023

Same journal

Ileal Pouch-Anal Anastomosis in the Older Adult: a Review of Postoperative Outcomes and Pouchitis Treatment.

Current treatment options in gastroenterology·2023

Same journal

Celiac Disease in the Elderly.

Current treatment options in gastroenterology·2023

See all related articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Biologic therapies offer new options for refractory ulcerative colitis and Crohn's disease. These advanced treatments, alongside traditional methods, aim to manage severe colonic inflammation and maintain remission effectively.

Area of Science:

Gastroenterology
Immunology
Pharmacology

Background:

Refractory colonic inflammation in ulcerative colitis (UC) and Crohn's disease (CD) presents significant treatment challenges.
Established therapies include corticosteroids and cyclosporine A for severe UC, and immunomodulators for remission maintenance in UC and CD.

Purpose of the Study:

To review current and emerging therapeutic options for refractory colonic inflammation in inflammatory bowel disease (IBD).
To highlight the efficacy of biologic therapies in managing severe or refractory cases of UC and CD.

Main Methods:

Review of current literature on therapeutic strategies for ulcerative colitis and Crohn's disease.
Analysis of the role of biologic agents, immunomodulators, and surgical interventions in IBD management.

Related Experiment Videos

Main Results:

Biologic therapies, particularly anti-tumor necrosis factor-alpha monoclonal antibodies, show high efficacy in severe or refractory Crohn's disease.
Immunomodulatory drugs like azathioprine, 6-mercaptopurine, and methotrexate are effective for maintaining remission in refractory IBD.
Experimental biologics offer alternatives for corticosteroid-dependent or non-responsive patients.

Conclusions:

The therapeutic landscape for refractory IBD has expanded with novel biologic agents.
A multi-faceted approach combining biologics, immunomodulators, and surgery is crucial for managing complex cases of ulcerative colitis and Crohn's disease.